ArticleWorld journal of surgical oncology2025
The delaying effect of toripalimab on disease progression in patients with advanced hepatocellular carcinoma and changes in serum tumor markers.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to retrospectively analyze the delaying effect of toripalimab on disease progression in patients with advanced HCC and to evaluate its impact on serum tumor marker levels.
methodsIn this single-center retrospective study, 80 advanced HCC patients treated between January 2021 and January 2023 were divided into two groups: the intervention group (n = 40) receiving TACE plus toripalimab (240 mg every 3 weeks), and the control group (n = 40) receiving TACE alone. Primary endpoints included objective response rate (ORR) and overall survival (OS); secondary endpoints encompassed tumor marker dynamics, liver function parameters, T lymphocyte subsets, and safety.
resultsThe intervention group exhibited significantly higher ORR compared to controls (70.0% vs. 35.0%, P = 0.002), with complete response (CR) in 25.0% of patients. Post-treatment tumor markers declined markedly in the intervention group: AFP (412.3 ± 98.5 to 156.7 ± 45.2 ng/mL, P < 0.001), HSP90α (68.4 ± 12.3 to 34.2 ± 8.7 ng/mL, P < 0.001), and CEA (15.2 ± 3.1 to 6.8 ± 1.9 ng/mL, P = 0.003). Liver function improved significantly (TBIL: 10.74 ± 1.14 vs. 15.47 ± 1.73 µmol/L; ALT: 24.97 ± 2.18 vs. 32.58 ± 2.25 U/L; both P < 0.001). The intervention group showed elevated CD4⁺ T cells (38.14 ± 2.69% vs. 32.56 ± 2.74%, P < 0.001) and CD4⁺/CD8⁺ ratio (1.38 ± 0.25 vs. 1.01 ± 0.33, P < 0.001). Adverse reactions were comparable (77.5% vs. 75.0%, P = 0.786), predominantly mild-to-moderate. After 2-year follow-up, median OS was significantly prolonged in the intervention group (20 vs. 16 months, P < 0.001), with a 77.5% survival rate versus 37.5% in controls (P < 0.001).
conclusionTACE combined with toripalimab demonstrates superior disease control in advanced HCC, marked by enhanced ORR, prolonged survival, reduced tumor biomarkers, improved liver function, and favorable immune modulation. The regimen exhibits acceptable safety, supporting its potential as a therapeutic option. Further prospective trials are needed to validate these findings and optimize combinatorial strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.